Trial · NCT00313911
Results by group122
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 122
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With High Fever Observed After Either DTaP-IPV-Hep B-PRP~T or Tritanrix Hep B/Hib™ + Placebo or Tritanrix-Hep B/Hib™ + Placebo Injection. | DTaP-IPV-Hep B-PRP~T | Post Any Dose (N = 1411, 703) | 56 | Participants | |
| Number of Participants With High Fever Observed After Either DTaP-IPV-Hep B-PRP~T or Tritanrix Hep B/Hib™ + Placebo or Tritanrix-Hep B/Hib™ + Placebo Injection. | Tritanrix-Hep B/Hib™ + OPV | Post Any Dose (N = 1411, 703) | 39 | 0 to 0 | Participants |
| Number of Participants With High Fever Observed After Either DTaP-IPV-Hep B-PRP~T or Tritanrix Hep B/Hib™ + Placebo or Tritanrix-Hep B/Hib™ + Placebo Injection. | DTaP-IPV-Hep B-PRP~T | Post Dose 1 (N = 1408, 703) | 5 | Participants | |
| Number of Participants With High Fever Observed After Either DTaP-IPV-Hep B-PRP~T or Tritanrix Hep B/Hib™ + Placebo or Tritanrix-Hep B/Hib™ + Placebo Injection. | Tritanrix-Hep B/Hib™ + OPV | Post Dose 1 (N = 1408, 703) | 4 | 0 to 0 | Participants |
| Number of Participants With High Fever Observed After Either DTaP-IPV-Hep B-PRP~T or Tritanrix Hep B/Hib™ + Placebo or Tritanrix-Hep B/Hib™ + Placebo Injection. | DTaP-IPV-Hep B-PRP~T | Post Dose 2 (N = 1348, 681) | 25 | Participants | |
| Number of Participants With High Fever Observed After Either DTaP-IPV-Hep B-PRP~T or Tritanrix Hep B/Hib™ + Placebo or Tritanrix-Hep B/Hib™ + Placebo Injection. | Tritanrix-Hep B/Hib™ + OPV | Post Dose 2 (N = 1348, 681) | 15 | 0 to 0 | Participants |
| Number of Participants With High Fever Observed After Either DTaP-IPV-Hep B-PRP~T or Tritanrix Hep B/Hib™ + Placebo or Tritanrix-Hep B/Hib™ + Placebo Injection. | DTaP-IPV-Hep B-PRP~T | Post Dose 3 (N = 1328, 672) | 26 | Participants | |
| Number of Participants With High Fever Observed After Either DTaP-IPV-Hep B-PRP~T or Tritanrix Hep B/Hib™ + Placebo or Tritanrix-Hep B/Hib™ + Placebo Injection. | Tritanrix-Hep B/Hib™ + OPV | Post Dose 3 (N = 1328, 672) | 23 | 0 to 0 | Participants |
| Geometric Mean Titers of Anti Hepatitis B Antibodies Following Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine + Placebo or Tritanrix-Hep B/Hib™ + Placebo | DTaP-IPV-Hep B-PRP~T | 1075 | 95% Confidence Interval 891 to 1298 | Titers | |
| Geometric Mean Titers of Anti Hepatitis B Antibodies Following Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine + Placebo or Tritanrix-Hep B/Hib™ + Placebo | Tritanrix-Hep B/Hib™ + OPV | 3376 | 95% Confidence Interval 2672 to 4338 | Titers | |
| Percentage of Participants Reaching Seroprotection Threshold Following Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine + Placebo or Tritanrix-Hep B/Hib™ + Placebo | DTaP-IPV-Hep B-PRP~T | ≥ 10 mIU/mL | 100 | Percentage of Participants | |
| Percentage of Participants Reaching Seroprotection Threshold Following Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine + Placebo or Tritanrix-Hep B/Hib™ + Placebo | Tritanrix-Hep B/Hib™ + OPV | ≥ 10 mIU/mL | 100 | 0 to 0 | Percentage of Participants |
| Percentage of Participants Reaching Seroprotection Threshold Following Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine + Placebo or Tritanrix-Hep B/Hib™ + Placebo | DTaP-IPV-Hep B-PRP~T | ≥ 100 mIU/mL | 96 | Percentage of Participants | |
| Percentage of Participants Reaching Seroprotection Threshold Following Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine + Placebo or Tritanrix-Hep B/Hib™ + Placebo | Tritanrix-Hep B/Hib™ + OPV | ≥ 100 mIU/mL | 99 | 0 to 0 | Percentage of Participants |
| Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Following Each Vaccination | DTaP-IPV-Hep B-PRP~T | Any Pain Post Dose 1 (N=1410, 703) | 831 | Participants | |
| Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Following Each Vaccination | Tritanrix-Hep B/Hib™ + OPV | Any Pain Post Dose 1 (N=1410, 703) | 574 | 0 to 0 | Participants |
| Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Following Each Vaccination | DTaP-IPV-Hep B-PRP~T | Severe Pain Post Dose 1 (N=1408, 703) | 175 | Participants | |
| Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Following Each Vaccination | Tritanrix-Hep B/Hib™ + OPV | Severe Pain Post Dose 1 (N=1408, 703) | 193 | 0 to 0 | Participants |
| Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Following Each Vaccination | DTaP-IPV-Hep B-PRP~T | Any Pain Post Dose 2 (N=1348, 681) | 744 | Participants | |
| Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Following Each Vaccination | Tritanrix-Hep B/Hib™ + OPV | Any Pain Post Dose 2 (N=1348, 681) | 506 | 0 to 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00313911/results